Initiation of phase 1 trial of remyelinating antibody
Posted: Tue Apr 23, 2013 10:49 pm
Initiation of phase 1 trial of remyelinating antibody in people with MS
Mayo Clinic and Acorda Therapeutics, Inc. announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). This is a Phase 1 clinical trial enrolling people with MS to assess the safety and tolerability of rHIgM22. The study also includes several exploratory efficacy measures....... Read More -http://www.ms-uk.org/index.cfm/myelin
Mayo Clinic and Acorda Therapeutics, Inc. announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). This is a Phase 1 clinical trial enrolling people with MS to assess the safety and tolerability of rHIgM22. The study also includes several exploratory efficacy measures....... Read More -http://www.ms-uk.org/index.cfm/myelin